92 related articles for article (PubMed ID: 2236167)
21. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
Ganser A; Ottmann OG; Hoelzer D
Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
[No Abstract] [Full Text] [Related]
22. Expression of messenger RNA for GM-CSF by blood mononuclear cells after allogeneic bone marrow transplantation.
Atkinson K; Altavilla V; Cooley M
Behring Inst Mitt; 1988 Aug; (83):330-4. PubMed ID: 3071349
[TBL] [Abstract][Full Text] [Related]
23. GM-CSF speeds recovery time following chemotherapy and bone-marrow transplant for solid tumors.
Oncology (Williston Park); 1991 Sep; 5(9):65. PubMed ID: 1835877
[No Abstract] [Full Text] [Related]
24. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide.
Rinehart J; Keville L; Neidhart J; Wong L; DiNunno L; Kinney P; Aberle M; Tadlock L; Cloud G
Am J Clin Oncol; 2003 Oct; 26(5):448-58. PubMed ID: 14528069
[TBL] [Abstract][Full Text] [Related]
25. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
26. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation (ASCT) in Hodgkin's disease: present status.
Angelo M; Carella AM
Pathol Biol (Paris); 1993 Jan; 41(1):107-9. PubMed ID: 7686282
[No Abstract] [Full Text] [Related]
28. GM-CSF allows higher doses of chemotherapy for sarcoma patients.
Oncology (Williston Park); 1991 Sep; 5(9):65-6. PubMed ID: 1835878
[No Abstract] [Full Text] [Related]
29. Treatment of acute myelogenous leukaemia.
Löwenberg B
J Intern Med Suppl; 1997; 740():17-22. PubMed ID: 9350177
[TBL] [Abstract][Full Text] [Related]
30. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Triozzi PL; Tucker F; Benzies T; Balcerzak SP
Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
[TBL] [Abstract][Full Text] [Related]
31. [Therapy of the recurrence of malignant lymphoma].
Brockmann B
Z Arztl Fortbild (Jena); 1992 Sep; 86(17):843-6. PubMed ID: 1384247
[No Abstract] [Full Text] [Related]
32. The role of colony stimulating factors in cancer therapy.
Morstyn G; Sheridan WP
Cancer Chemother Biol Response Modif; 1991; 12():307-26. PubMed ID: 1718376
[No Abstract] [Full Text] [Related]
33. Marketing of recombinant granulocyte-macrophage colony-stimulating factor approved by FDA.
Clin Pharm; 1991 Jun; 10(6):411. PubMed ID: 2065520
[No Abstract] [Full Text] [Related]
34. Guillain-Barre syndrome following autologous bone marrow transplantation.
Mudad R; Hussein A; Peters WP
Am J Clin Oncol; 1995 Apr; 18(2):167-9. PubMed ID: 7900710
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer.
Schmid L; Thürlimann B; Müller M; Senn HJ
Recent Results Cancer Res; 1991; 121():173-81. PubMed ID: 1857857
[No Abstract] [Full Text] [Related]
36. Granulocyte-macrophage colony-stimulating factor (GM-CSF): answers or more questions?
Vose JM; Bierman PJ; Armitage JO
Ann Intern Med; 1992 Feb; 116(3):261-2. PubMed ID: 1728209
[No Abstract] [Full Text] [Related]
37. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.
El-Saghir N; Otrock Z; Mufarrij A; Abou-Mourad Y; Salem Z; Shamseddine A; Abbas J
Lancet Oncol; 2004 May; 5(5):320-1. PubMed ID: 15120669
[No Abstract] [Full Text] [Related]
38. High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factor.
Venturini M; Del Mastro L; Ardizzoni A; Sertoli MR; Mariani GL; Pennucci MC; Garrone O; Silvestro S; Addamo GF; Queirolo P
Ann N Y Acad Sci; 1993 Nov; 698():389-97. PubMed ID: 8279779
[No Abstract] [Full Text] [Related]
39. Hematologic recovery after marrow-ablative chemotherapy and peripheral blood stem cell transplantation in children.
Matsuzaki A; Kai T; Ohga S; Nomura A; Inaba S; Harada M; Ishii E; Ueda K
Pediatr Hematol Oncol; 1995; 12(2):201-4. PubMed ID: 7626391
[No Abstract] [Full Text] [Related]
40. Interleukin 3: biological and clinical effects.
Oster W; Schulz G
Int J Cell Cloning; 1991 Jan; 9(1):5-23. PubMed ID: 2010655
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
